About the Systemic Psoriasis Therapeutics Market
Psoriasis is a commonly diagnosed immune-mediated disease of the skin. In psoriasis, the skin grows fast and causes a build-up of red, thick white, or silvery patches. It modifies the normal cell cycle of the skin such that new cells move to the surface of the skin quickly to form patches called plaques. These plaques are commonly found on the knees, elbows, scalp, hand and feet. The condition mostly occurs among adults (18 years-35 years), but can also be seen in adolescents (12 years-18 years) and children (under 10 years).
Psoriasis is more prevalent among Caucasians compared to African-Americans. According to a World Health Organization (WHO) document of 2015, the global prevalence of psoriasis is approximately 2%-3%. However, it is approximately 4.6% in developed countries. In addition, the risk of an individual getting diagnosed with psoriasis is 41% if both parents have psoriasis, 14% in case one parent is affected, and 6% if a sibling has psoriasis.
Technavio’s analysts forecast the global systemic psoriasis therapeutics market to grow at a CAGR of 9.41% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global systemic psoriasis therapeutics market for 2016-2020. To calculate the market size, Technavio considers the revenue generated from the from the sales of branded, generic, and off-label drugs used to treat psoriasis. It also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of marketed drugs during the forecast period.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Systemic Psoriasis Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• AbbVie
• Johnson & Johnson
• Celgene
• Amgen
• Pfizer
Other prominent vendors
• AbGenomics
• Almirall
• Anacor Pharmaceuticals
• ApoPharma
• Astellas Pharma
• AstraZeneca
• Aurinia Pharmaceuticals
• Biocon
• Biogen Idec
• Biotest
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Can-Fite BioPharma
• Cellceutix Corporation
• Coherus Biosciences
• Creabilis
• Crescendo Biologics
• Delenex Therapeutics
• Dermira
• Eli Lilly
• F. Hoffmann-La Roche
• Forward Pharma
• G & W Laboratories
• GlaxoSmithKline
• Idera Pharmaceuticals
• Incyte
• Kadmon
• kinetabio
• KPI Therapeutics
• Kyowa Hakko Kirin
• LEO Pharma
• Maruho
• Merck
• Mitsubishi Tanabe Pharma
• Moleculin
• MorphoSys
• Novartis
• Prism Pharma
• Promius Pharma
• Prothena Biosciences
• Provectus Biopharmaceuticals
• Sandoz
• Sun Pharmaceuticals
• Takeda Pharmaceuticals
• Taro Pharmaceuticals
• TFS
• UCB
• Valeant Pharmaceuticals
• VBL Therapeutics
• XenoPort
• Ziarco Pharma
Market driver
• Dominance of market by biologics
• For a full, detailed list, view our report
Market challenge
• Physician's reluctance to prescribe biosimilars
• For a full, detailed list, view our report
Market trend
• Advent of biologics with novel MOA and cell-based strategies
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Assumptions
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Psoriasis: Condition overview
• Prevalence
• Economic burden of psoriasis
PART 06: Pipeline analysis
• Novel mechanisms targeted by pipeline candidates
PART 07: Market landscape
• Market overview
• Five forces analysis
PART 08: Market segmentation by type of molecule
• Global biologics market
• Small molecules
PART 09: Market segmentation by mechanism of action
• TNF inhibitors
• PDE4 inhibitors
• IL blockers
• Others
PART 10: Market segmentation by severity of disease
• Mild psoriasis
• Moderate psoriasis
• Severe psoriasis
PART 11: Market segmentation by ROA
• Oral
• Parenteral
PART 12: Geographical segmentation
• Systemic psoriasis therapeutics market in Americas
• Systemic psoriasis therapeutics market in US
• Systemic psoriasis therapeutics market in EMEA
• Systemic psoriasis therapeutics market in APAC
PART 13: Market drivers
• Dominance of market by biologics
• Increase in psoriatic patient pool due to new diagnostic procedures
• Recurrence of psoriasis
• Expected approval of late-stage pipeline molecules
PART 14: Impact of drivers
PART 15: Market challenges
• Physician's reluctance to prescribe biosimilars
• Innovative blue LED device and magnetic therapy as potential therapeutics substitutes
• Unknown disease etiology
• Use of CAM and topical drugs to treat psoriasis
PART 16: Impact of drivers and challenges
PART 17: Market trends
• Advent of biologics with novel MOA and cell-based strategies
• Emergence of next-generation systemic psoriatic therapies
• Preference for combination therapies
• Popularity of off-label systemic medications
PART 18: Vendor landscape
• Competitive scenario
• Upcoming vendors
• Key news
• AbbVie
• Johnson & Johnson
• Celgene
• Amgen
• Pfizer
• Other prominent vendors
PART 19: Appendix
• List of abbreviations
PART 20: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Economic burden of psoriasis
Exhibit 03: Annual treatment costs of psoriasis 2014 ($)
Exhibit 04: Global systemic psoriasis therapeutics market: Pipeline portfolio
Exhibit 05: Pipeline share of molecules in different stages of development 2015
Exhibit 06: Novel targets of pipeline candidates
Exhibit 07: Share of novel pipeline molecules based on their MOA 2015
Exhibit 08: Approvals and patent expiries of top selling biologics
Exhibit 09: Global systemic psoriasis therapeutics market 2015-2020 ($ billions)
Exhibit 10: Global systemic psoriasis therapeutics market snapshot: Developed and emerging markets 2015
Exhibit 11: A few patient assistance programs offered by various companies
Impact of drivers and challenges on the market
Exhibit 12: Impact of key customer segments on market 2015
Exhibit 13: Opportunities faced by psoriasis industry today
Exhibit 14: Five forces analysis
Exhibit 15: Global systemic psoriasis therapeutics market: Segmentation by type of molecule (2015-2020)
Exhibit 16: Global systemic psoriasis therapeutics market: Segmentation by type of molecule 2015
Exhibit 17: Competitive assessment of marketed and late-stage pipeline molecules
Exhibit 18: Global biologics market 2015-2020 ($ billions)
Exhibit 19: Opportunity analysis of global systemic psoriasis therapeutics market by type of molecule
Exhibit 20: Impact of biologics on various sectors
Exhibit 21: Global small molecules market 2015-2020 ($ millions)
Exhibit 22: Average percentage of patients receiving TNF inhibitors 2010 and 2015
Exhibit 23: Global systemic psoriasis therapeutics market segmentation by MOA 2015
Exhibit 24: Global systemic psoriasis therapeutics market segmentation by MOA 2020
Exhibit 25: Global systemic psoriasis therapeutics market segmentation by severity of disease 2015
Exhibit 26: Global systemic psoriasis therapeutics segmentation by ROA 2015
Exhibit 27: Global systemic psoriasis therapeutics market: Geographical outlook (2015-2020)
Exhibit 28: Global systemic psoriasis therapeutics market: Geography outlook 2015
Exhibit 29: Revenue/growth outlook in different countries/regions 2015
Exhibit 30: Systemic psoriasis therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 31: Systemic psoriasis therapeutics market in America by country 2015
Exhibit 32: Systemic psoriasis therapeutics market in US 2015-2020 ($ billions)
Exhibit 33: Systemic psoriasis therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 34: Systemic psoriasis therapeutics market in APAC 2015-2020 ($ billions)
Exhibit 35: Global systemic psoriasis therapeutics market by geographical segmentation 2015
Exhibit 36: Global systemic psoriasis therapeutics market by geographical segmentation 2020
Exhibit 37: Global systemic psoriasis therapeutics market revenue by geography 2015-2020 ($ billions)
Exhibit 38: Biologicals approvals by US FDA
Exhibit 39: List of some pipeline molecules
Exhibit 40: Impact of drivers
Exhibit 41: Key reasons to prescribe biosimilars 2015
Exhibit 42: CAM and topical drugs for psoriasis
Exhibit 43: Usage of CAMs in US 2014
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Psoriasis market: Impact assessment of top trends 2015
Exhibit 46: Market share of major vendors for global systemic psoriasis therapeutics market 2015
Exhibit 47: Competitive assessment of vendors
Exhibit 48: Key vendors: Geographical presence 2015
Exhibit 49: YoY sales comparison of top selling drugs 2013-2015 ($ billions)
Exhibit 50: Upcoming vendors
Exhibit 51: AbbVie: Product segmentation by revenue 2015
Exhibit 52: AbbVie: YoY revenue and growth rate of Humira 2013-2015 ($ billions)
Exhibit 53: AbbVie: YoY revenue and growth rate of Humira (in US) 2013-2015 ($ billions)
Exhibit 54: AbbVie: YoY revenue and growth rate of Humira (ROW) 2013-2015 ($ billions)
Exhibit 55: AbbVie: Metrics analysis
Exhibit 56: Johnson & Johnson: YoY growth rate and revenue of Remicade 2013-2015 ($ billions)
Exhibit 57: Johnson & Johnson: YoY growth rate and revenue of Remicade (in US) 2013-2015 ($ billions)
Exhibit 58: Johnson & Johnson: YoY growth rate and revenue of Remicade (ROW) 2013-2015 ($ billions)
Exhibit 59: Johnson & Johnson: YoY growth rate and revenue of Stelara 2013-2015 ($ billions)
Exhibit 60: Johnson & Johnson: YoY growth rate and revenue of Stelara (in US) 2013-2015 ($ millions)
Exhibit 61: Johnson & Johnson: YoY growth rate and revenue of Stelara (ROW) 2013-2015 ($ millions)
Exhibit 62: Johnson & Johnson: Metrics analysis
Exhibit 63: Celgene: YoY revenue comparison of Otezla 2014-2015 ($ millions)
Exhibit 64: Celgene: Metrics analysis
Exhibit 65: Amgen: YoY revenue and growth rate of Enbrel (in US and Canada) 2013-2015 ($ billions)
Exhibit 66: Amgen: YoY revenue and growth rate of Enbrel (in US) 2013-2015 ($ billions)
Exhibit 67: Amgen: YoY revenue and growth rate of Enbrel (in Canada) 2013-2015 ($ millions)
Exhibit 68: Amgen: Metrics analysis
Exhibit 69: Pfizer: YoY revenue and growth rate of Enbrel (outside US and Canada) 2013-2015 ($ billions)
Exhibit 70: Pfizer: Metrics analysis
